EXTH-49. A NOVEL THERAPEUTIC ANTIBODY TARGETING DIFFUSE MIDLINE GLIOMA

نویسندگان

چکیده

Abstract There is an unmet need to identify novel targeted therapies for H3K27M mutated Diffuse Midline Gliomas. (DMG) Using genetic overexpression and deletion of in model cells we identified high expression CD99 mRNA H3K27M-mutant expressing DIPGs compared other normal brain counterparts. A cell surface antigen screen confirmed that was highly expressed DMG tissues. We then developed a chimeric antibody based on human IgG4 scaffold tested the anti-tumor efficacy this vitro vivo xenografts. Our new (10D1) significantly reduced DIPG tumor proliferation vitro. In intravenous administration orthotopic bearing mice showed complete clearance with prolonged animal survival establishing 10D1 demonstrating its ability crossing blood-brain-pons barrier. Loco-regional 10D1, intratumorally or lateral ventricle, similar effects at concentrations while limiting systemic T cells. combined radiation further prolong xenograft-bearing animals. conclusion, have therapeutic which now development.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dalteparin as a Novel Therapeutic Agent to Prevent Diabetic Encephalopathy by Targeting Oxidative Stress and Inflammation

Introduction: Hepcidin is the principal modulator of systemic iron metabolism, and its role in the brain has been clarified recently. Studies have shown hepcidin plays an important role for in neuronal iron load and inflammation. This is of significance because neuronal iron load and inflammation are pathophysiological processes that have been highly linked to neurodegeneration. Moreover, the a...

متن کامل

A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α

Hsp90a's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using the post-transcriptional RNAi strategy (sihsp90a) and a post-translational inhibitor, the benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and no...

متن کامل

Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma

Recent studies have identified that K27M mutation in either the H3F3A or HIST1H3B genes, which encode the histone H3 variants H3.3 and H3.1, define the majority of diffuse gliomas arising in midline structures including the thalamus, brainstem, and spinal cord in both children and adults [8, 10]. These “diffuse midline gliomas, H3 K27M-mutant” are associated with poor prognosis regardless of hi...

متن کامل

MicroRNA targeting as a therapeutic strategy against glioma.

Glioblastoma multiforme (GBM), the most common and aggressive form of primary brain tumor, presents a dismal prognosis. Current standard therapies are only able to improve patient survival by a few months. The search for alternative approaches in glioblastoma treatment, together with the recent discovery of a new class of small RNA molecules that are capable of regulating gene expression, promp...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Neuro-oncology

سال: 2022

ISSN: ['1523-5866', '1522-8517']

DOI: https://doi.org/10.1093/neuonc/noac209.847